Treatment of Gastroenteropancreatic Neuroendocrine Tumors with Peptide Receptor Radionuclide Therapy

Publisher： Karger

E-ISSN： 1423-0194|97|1|74-85

ISSN： 0028-3835

Source： Neuroendocrinology, Vol.97, Iss.1, 2012-01, pp. : 74-85

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs

By  

Neuroendocrinology, Vol. 90, Iss. 2, 2009-08 ,pp. : 220-226

Karger

Access to resources Recommend Favorite

Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC and 177Lu-DOTATOC in Advanced Neuroendocrine Tumors: Results from a Danish Cohort Treated in Switzerland

By  

Neuroendocrinology, Vol. 93, Iss. 3, 2011-02 ,pp. : 189-196

Karger

Access to resources Recommend Favorite

Epigenetic Aspects on Therapy Development for Gastroenteropancreatic Neuroendocrine Tumors

By  

Neuroendocrinology, Vol. 97, Iss. 1, 2012-03 ,pp. : 19-25

Karger

Access to resources Recommend Favorite

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues

By  

Neuroendocrinology, Vol. 105, Iss. 3, 2017-04 ,pp. : 295-309

Karger

Access to resources Recommend Favorite

Therapeutic Monitoring of Gastroenteropancreatic Neuroendocrine Tumors: The Challenges Ahead

By  

Neuroendocrinology, Vol. 96, Iss. 4, 2012-10 ,pp. : 261-271

Karger

Access to resources Recommend Favorite